Product Description
HSD-016 was discovered as an orally efficacious 11_-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of diabetes. (Sourced from: https://drugs.ncats.io/drug/C4I13768E1)
Mechanisms of Action: 11beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00838461 |
3248A1-1002 | P1 |
Completed |
Healthy Volunteers |
2009-06-01 |
2019-03-18 |
Treatments |
|
NCT00740649 |
3248A1-1001 | P1 |
Completed |
Healthy Volunteers |
2009-03-01 |
2019-03-18 |
Treatments |
|
NCT00739232 |
3248A1-1000 | P1 |
Completed |
Healthy Volunteers |
2009-02-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|